These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 16998297)

  • 21. Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C.
    Choi JW; Lee JS; Paik WH; Song TJ; Kim JW; Bae WK; Kim KA; Kim JG
    Clin Mol Hepatol; 2016 Mar; 22(1):168-71. PubMed ID: 27044768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C].
    Shin MK; Kim TH; Ju K; Ha CY; Min HJ; Jung WT; Lee OJ
    Korean J Hepatol; 2009 Sep; 15(3):370-4. PubMed ID: 19783887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial.
    Bruno S; Cammà C; Di Marco V; Rumi M; Vinci M; Camozzi M; Rebucci C; Di Bona D; Colombo M; Craxì A; Mondelli MU; Pinzello G
    J Hepatol; 2004 Sep; 41(3):474-81. PubMed ID: 15336451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
    Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS
    Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ; Romagosa R; Vincek V
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract]   [Full Text] [Related]  

  • 27. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
    Yu ML; Dai CY; Huang JF; Hou NJ; Lee LP; Hsieh MY; Chiu CF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Gut; 2007 Apr; 56(4):553-9. PubMed ID: 16956917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Irsogladine maleate for the treatment of recurrent aphthous stomatitis in hepatitis C virus patients on pegylated-interferon and ribavirin: a pilot study.
    Hayashi N; George J; Shiroeda H; Saito T; Toshikuni N; Tsuchishima M; Arisawa T; Tsutsumi M
    J Gastroenterol Hepatol; 2013 Jun; 28(6):1015-8. PubMed ID: 23425065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Autoimmune hepatitis and membranous glomerulonephritis under immune therapy in chronic hepatitis C].
    Paparoupa M; Huy Ho NA; Schuppert F
    Dtsch Med Wochenschr; 2016 May; 141(10):709-11. PubMed ID: 27176065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin: case report and literature review].
    Cacopardo B; Pinzone MR; Nunnari G
    Infez Med; 2013 Mar; 21(1):40-44. PubMed ID: 23524900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
    Roomer R; Hansen BE; Janssen HL; de Knegt RJ
    Hepatology; 2010 Oct; 52(4):1225-31. PubMed ID: 20830784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
    Kang HM; Park MJ; Hwang JM; Kim JW; Jeong SH
    Korean J Hepatol; 2009 Jun; 15(2):209-15. PubMed ID: 19581773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
    Testino G; Gentile R; Ansaldi F; Borro P; Ravetti G; Icardi G; Sumberaz A
    Panminerva Med; 2009 Jun; 51(2):135-6. PubMed ID: 19776716
    [No Abstract]   [Full Text] [Related]  

  • 34. Fulminant autoimmune hepatitis after successful interferon treatment in an HIV-HCV co-infected patient.
    Coriat R; Podevin P
    Int J STD AIDS; 2008 Mar; 19(3):208-10. PubMed ID: 18397566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin].
    Kim YH; Han WS; Lee SJ; Oh SN; Choi DW; Byun KS; Yeon JE
    Korean J Hepatol; 2007 Sep; 13(3):419-22. PubMed ID: 17898559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C.
    Fontana RJ; Bieliauskas LA; Lindsay KL; Back-Madruga C; Wright EC; Snow KK; Lok AS; Kronfol Z; Padmanabhan L;
    Hepatology; 2007 May; 45(5):1154-63. PubMed ID: 17465000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C.
    Casale M; Mazzarelli C; Vespasiani Gentilucci U; Potena M; Pappacena M; Faiella F; Galati G; Salvinelli F; Picardi A
    Int J Immunopathol Pharmacol; 2012; 25(2):551-6. PubMed ID: 22697091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Hayashi M; Kataoka Y; Tachikawa K; Koguchi H; Tanaka H
    Diabetes Res Clin Pract; 2009 Nov; 86(2):e19-21. PubMed ID: 19744739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
    Kartal ED; Alpat SN; Ozgunes I; Usluer G
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):817-20. PubMed ID: 17700271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    Grossmann Sde M; Teixeira R; de Aguiar MC; do Carmo MA
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):702-6. PubMed ID: 18679075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.